These innovative agents represent a significant progression in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose https://heathgiyp511434.bloginder.com/39813651/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide